McCarthy Christopher reported option exercise involving 277,009 shares of INTERPACE BIOSCIENCES, INC. at $0.00 for $0 on Aug 20, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CFO & COO
CFO & COO
Filed Aug 20, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
277,009Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
323,800Direct
Trade date
Aug 20, 2026Option exercise
Filed
Aug 20, 2026, 4:59 PM ET0-day reporting delay
Accession
0001493152-26-039495Code M · Transaction 13199
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 20, 2026Grant277,009$0.00$0Trade 13202
Aug 20, 2026Option exercise277,009$0.00$0Trade 13201
Aug 20, 2026Grant554,018$0.00$0Trade 13200
4 transaction rows in this filing. Joint filers share the same rows.

IDXG price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IDXG · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Aug 27, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date. F2: Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc. F3: On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date. F4: The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.